- Home
- ANTX vs FGEN Comparison
ANTX vs FGEN Comparison
Compare ANTX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | FGEN |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 35.6M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANTX | FGEN |
|---|---|---|
| Price | $1.10 | $8.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $146.50 |
| AVG Volume (30 Days) | ★ 61.1K | 41.5K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | N/A | ★ $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.16 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $4.85 |
| 52 Week High | $1.55 | $21.94 |
Technical Indicators
Market Signals| Indicator | ANTX | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 46.09 |
| Support Level | $1.03 | $8.30 |
| Resistance Level | $1.23 | $10.47 |
| Average True Range (ATR) | 0.08 | 0.58 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 55.00 | 15.85 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.